Redeye comments on ExpreS2ion’s announcement of a planned fully pre-emptive rights issue of approximately SEK53m, aimed at funding completion of the ongoing phase I trial with ES2B-C001 and strengthening the company’s operational platform. While the financing is necessary to secure near-term clinical milestones, it will be dilutive and may weigh on the share in the short term. At the same time, we view the raise as an important step in reducing execution risk ahead of key phase I readouts and continued partnering efforts.
LÄS MER
